Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.36 0.27 −2.80%
Market cap
$681.6M
P/E
62.4×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
92.60 87.58 441.75 1,450.00

+8 more quarters

P/S ratio
2.02 3.35 3.24 2.73
P/FCF ratio
21.56 22.24 22.56 18.76
P/Operating CF
(76.70) 634.83 113.67 30.87
P/B ratio
2.74 4.61 4.39 3.74
EV/Sales
1.86 3.16 3.02 2.54
EV/EBITDA
22.26 29.38 30.63 21.93
EV/FCF
19.80 20.95 21.04 17.46
Current Ratio
3.01 2.63 2.59 3.16
Net Debt/EBITDA
(13.93) 40.19 (8.62) (3.70)
Debt/Equity
0.36 0.37 0.35 0.37
Earnings Yield
1.08% 1.14% 0.23% 0.07%
Free Cash Flow Yield
4.64% 4.50% 4.43% 5.33%
Free Cash Flow per Share
(0.18) 0.02 0.15 0.47
Book value per Share
5.07 3.61 4.02 3.88
Free Cash Flow
(9.74) 1.71 10.44 31.96
EV/EBIT
36.83 41.72 43.93 35.06
Other line items

Show all line items

Columns are period end dates